Pretreatment and acquired HIV drug resistance in Belize-results of nationally representative surveys, 2021-22.

ABSTRACT:

Background

The rising prevalence of pretreatment drug resistance (PDR) to non-nucleoside reverse-transcriptase inhibitors threatens the effectiveness of ART. In response, the WHO recommends dolutegravir-based ART regimens due to their high genetic barrier to resistance and better treatment outcomes. This is expected to contribute to achieving the Joint United Nations Programme on HIV/AIDS (UNAIDS) target of 95% viral suppression in people on ART.

Objectives

To estimate the prevalence of PDR among adults initiating ART and assess viral suppression and acquired HIV drug resistance (ADR) among individuals receiving ART in Belize.

Patients and methods

Nationally representative cross-sectional PDR and ADR surveys were conducted between 2021 and 2022. Sixty-seven adults wer

SUBMITTER: Morey F 

PROVIDER: S-EPMC11695872 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature